Iridian Asset Management LLC CT Purchases 1,465,962 Shares of Precigen, Inc. (NASDAQ:PGEN)

Iridian Asset Management LLC CT increased its position in Precigen, Inc. (NASDAQ:PGEN) by 38.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,241,922 shares of the biotechnology company’s stock after purchasing an additional 1,465,962 shares during the quarter. Precigen makes up 1.6% of Iridian Asset Management LLC CT’s holdings, making the stock its 21st largest position. Iridian Asset Management LLC CT owned about 1.79% of Precigen worth $5,871,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of PGEN. Geode Capital Management LLC increased its holdings in shares of Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after purchasing an additional 149,829 shares during the last quarter. State Street Corp raised its holdings in Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after acquiring an additional 29,253 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 127,467 shares during the last quarter. LexAurum Advisors LLC boosted its holdings in shares of Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after acquiring an additional 417,055 shares during the period. Finally, FMR LLC grew its position in shares of Precigen by 26.4% in the third quarter. FMR LLC now owns 345,204 shares of the biotechnology company’s stock valued at $327,000 after purchasing an additional 72,033 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on PGEN shares. HC Wainwright reissued a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Precigen in a report on Thursday, January 23rd. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Precigen in a report on Tuesday, January 14th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Performance

Shares of PGEN stock opened at $1.60 on Friday. Precigen, Inc. has a twelve month low of $0.65 and a twelve month high of $1.93. The business has a fifty day simple moving average of $1.03 and a 200 day simple moving average of $1.04.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.